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Hyaluronidase HYAL-2 is a membrane-anchored protein and also localizes, in part,
in the lysosome. Recent study from animal models revealed that both HYAL-1 and
HYAL-2 are essential for the metabolism of hyaluronan (HA). Hyal-2 deficiency is
associated with chronic thrombotic microangiopathy with hemolytic anemia in mice
due to over accumulation of high molecular size HA. HYAL-2 is essential for platelet
generation. Membrane HYAL-2 degrades HA bound by co-receptor CD44. Also, in a
non-canonical signal pathway, HYAL-2 serves as a receptor for transforming growth
factor beta (TGF-β) to signal with downstream tumor suppressors WWOX and SMAD4
to control gene transcription. When SMAD4 responsive element is overly driven by the
HYAL-2–WWOX–SMAD4 signaling complex, cell death occurs. When rats are subjected
to traumatic brain injury, over accumulation of a HYAL-2–WWOX complex occurs in the
nucleus to cause neuronal death. HA induces the signaling of HYAL-2–WWOX–SMAD4
and relocation of the signaling complex to the nucleus. If the signaling complex is
overexpressed, bubbling cell death occurs inWWOX-expressing cells. In addition, a small
synthetic peptide Zfra (zinc finger-like protein that regulates apoptosis) binds membrane
HYAL-2 of non-T/non-B spleen HYAL-2+ CD3− CD19− Z lymphocytes and activates the
cells to generate memory anticancer response against many types of cancer cells in vivo.
Whether the HYAL-2–WWOX–SMAD4 signaling complex is involved is discussed. In this
review and opinion article, we have updated the current knowledge of HA, HYAL-2 and
WWOX, HYAL-2–WWOX–SMAD4 signaling, bubbling cell death, and Z cell activation for
memory anticancer response.
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INTRODUCTION
High molecular weight hyaluronan (HA) is accounted for approximately 0.02% of a human body
weight (e.g., 16 g HA in an 80 kg individual), in which one third of the amount undergoes daily
turnover (Stern, 2004; Viola et al., 2015; Chanmee et al., 2016). Hyaluronidases play a key role in
the catabolism of HA. Apparently, the highly active turnover of HA is of physiological significance,
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and degraded small HA fragments play important physiological
and pathological roles such as in cancer metastasis (Bertrand
et al., 1992; Josefsson et al., 2011; Lokeshwar et al., 2014).
Urinary excretion of degraded HA of 400–12,000 Daltons is
around 330 µg daily (Laurent et al., 1987). Excessive amounts
of small HA fragments can be found in urine, plasma and
cancer lesions from cancer patients (Laurent et al., 1987;
Turley et al., 2016). HA is accumulated in the extracellular
matrix in the brains of patients suffering neurodegeneration
(Sherman et al., 2015). The elevated HA accumulation in the
brain may occur as a result of injury to neurons, glial cells
and surrounding brain tissues (Sherman et al., 2015). HA
contributes to the control of cell proliferation, migration and
differentiation (Sherman et al., 2015; Turley et al., 2016). A
recent study showed that HA does not contribute to the growth
and differentiation of human epidermal keratinocyte (Malaisse
et al., 2016). Nevertheless, UDP-glucose induces HA synthesis in
keratinocytes via P2Y14 receptor, STAT3 signaling and activation
of hyaluronan synthase (HAS) promoter (Jokela et al., 2014). The
conformation of HA in solution is readily subjected to changes
upon altering the compositions of solvents, and this affects the
functional properties of HA in many biological processes such
as interactions with complement proteins and their associated
hemolytic function (Chang and Boackle, 1985; Chang et al.,
1985; Hong et al., 2007b). For example, under low ionic strength
conditions, HA has a less compact conformation in the saliva that
allows its interactions with complement proteins and bacteria
(Chang and Boackle, 1986).
HA AND HYALURONAN SYNTHASE (HAS)
HA is a non-sulfated glycosaminoglycan, consisting of
repeating disaccharide units of D-glucuronic acid and
D-N-acetylglucosamine, which links through alternating
beta-1,4 and beta-1,3 glycosidic bonds (Laurent et al., 1987;
Cyphert et al., 2015; Turley et al., 2016). The disaccharide unit of
HA repeats 10,000 or more times, reaching a molecular mass of
∼4 million Daltons (each disaccharide∼ 400 Daltons; Yeh et al.,
2011). HA chains are highly hydrophilic and have hydrophobic
patches. HA forms twofold helix, expands tremendously
in aqueous solutions, and forms a meshwork-liked tertiary
structure through β-sheets (Heatley and Scott, 1988; Scott et al.,
1991). High-molecular-mass HA (105 saccharides, 2 × 104 kDa)
in synovial fluid and vitreous humor may act like a barrier to
other molecules and cells, so they have anti-angiogenic, anti-
inflammatory, and immunosuppressive effects. Indeed, fairly
high molecular mass of HA, which is more than 5 times larger
than human or mouse HA, confers resistance to cancer in naked
mole rat (Tian et al., 2013). Small HA fragments induce the
release of inflammatory chemokines, stimulate CD44 cleavage,
increase angiogenesis, and promote tumor cell migration (Ghosh
et al., 2015; Monslow et al., 2015).
HA distribution and abundance in tissues is tightly regulated
by hyaluronan synthases (HAS1, HAS2, and HAS3) and
hyaluronidases (HYAL1, HYAL2, and HYAL3). HAS are
membrane-bound glycosyltransferases that act on alternating
UDP-α-D-glucuronate (from pentose phosphate pathway) and
UDP-α-N-acetyl-D-glucosamine (from glycolysis) to produce
HA (Lee and Spicer, 2000; Itano and Kimata, 2002). HAS1,
for example, adds new intracellular sugar-UDPs at the reducing
end of growing hyaluronyl-UDP chains (Weigel, 2015). Presence
of heterodimeric complexes of HAS1-HAS2, HAS2-HAS2,
and HAS2-HAS3 has been reported (Bart et al., 2015). As
established in Has knockout mice, Has2 is important for
embryo development, while Has1 and Has3 have no effects
(Camenisch et al., 2000; Bai et al., 2005). Has1 is frequently
upregulated in inflammatory diseases such as atherosclerosis,
osteoarthritis, and infectious lung diseases (Siiskonen et al.,
2015). By using recombinant HAS, synthesized HA is 2 × 105–
2 × 106 Daltons by HAS1, 2 × 106 by HAS2, and 105–106
by HAS3 (Itano and Kimata, 2002). Deficiency of HAS and
hyaluronidases contributes to numerous types of diseases. For
example, mucopolysaccharidosis IX is due to lack of HYAL-1 and
HAS2 in a single person having cardiac pathology (Triggs-Raine
and Natowicz, 2015).
It is generally believed that high molecular weight HA
provides a space-filling function for tissues and organs (Lee and
Spicer, 2000). In this case, HA is strong in anti-inflammation,
anti-angiogenesis and anti-cancer growth, and supports wound
healing (Tian et al., 2013; Tolg et al., 2014; Schwertfeger
et al., 2015; Litwiniuk et al., 2016). In contrast, low molecular
weight HA is capable of stimulating angiogenesis, provoking
proinflammation, and supporting cancer growth (Tian et al.,
2013; Schwertfeger et al., 2015; Litwiniuk et al., 2016). These
aforementioned scenarios may not necessarily be true. The long-
chain HA can be physically altered and partially degraded. Due to
the altered conformation and reduced sizes, HA is able to achieve
a great potency in anti-inflammation and blocking cancer growth
(Chang and Su, 2016).
HA RECEPTORS AND SIGNALING
There are many HA receptors identified, whereas their
binding affinities with native HA, conformationally altered
HA, and HA fragments have been poorly defined. Among the
most studied receptor proteins are CD44 and receptor for
hyaluronan-mediated motility (RHAMM), as they participate
in inflammation and cancer motility, migration and metastasis
(Slevin et al., 2007; Lokeshwar et al., 2014; Tolg et al.,
2014; Misra et al., 2015). Furthermore, both CD44 and
RHAMM are associated with the development of stem cell
and cancer stem cell (Jiang et al., 2013; Shigeishi et al., 2013;
Kouvidi et al., 2014; Jordan et al., 2015). FAK/SRC-mediated
ERK activation is involved in signaling event for stem cell
development. Additional receptor proteins for HA include
intracellular adhesion molecule-1 (ICAM-1) (Bruynzeel et al.,
1993), hyaluronan receptor for endocytosis (HARE) (Pandey
and Weigel, 2014), and lymphatic vessel endothelial hyaluronan
receptor (LYVE)-1 (Banerji et al., 1999; Lawrance et al., 2016).
Clustering of LYVE-1 is essential for HA binding in the lymphatic
endothelial cells (Lawrance et al., 2016). The sizes of HA affect
CD44 clustering (Yang et al., 2012). Notably, CD147 (also known
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as emmprin or basigin) is shown to control HA synthesis
and interact with the HA receptors CD44 and LYVE-1. These
interactions appear to contribute to drug transporter-associated
chemoresistance (Grass et al., 2014).
HYALURONIDASES AND CLINICAL
RELEVANCE AND APPLICATIONS
Hyaluronidases cleave the β-1,4-glucosaminidic bond between
glucosamine and glucuronic acid (Girish and Kemparaju,
2007). These enzymes have been widely utilized in clinical
applications. Hyaluronidases are utilized as adjuvants to destruct
the extracellular matrix to enhance the penetration of drugs to
target areas in the body (Buhren et al., 2016). Six hyaluronidase-
like genes in humans have been identified, which are HYAL1,
HYAL2, HYAL3, HYAL4, PH-20/SPAM1, and a pseudogene
HYALP1 (Csoka et al., 2001; Stern and Jedrzejas, 2006). HYAL1,
HYAL2, and HYAL3 are clustered on the chromosome 3p21.3,
and HYAL4, HYALP1 (a pseudogene), and SPAM1 (sperm
adhesion molecule 1) on chromosome 7p31.3. HYAL-1 is present
in many tissues and found in the circulation, and is internalized
by monocytes and endothelial cells to relocate in the lysosomes
(Frost et al., 1997; Csoka et al., 2001; Puissant et al., 2014). HYAL-
1 is functionally active at low pH (pH = 3.8). Hyaluronidases
HYAL-1 and PH-20, but not HYAL-2, can be found in secretion.
HYAL-2 has a 20-amino-acid signal sequence at the C-
terminus that allows the formation of a GPI linkage onto the
cell membrane (Rai et al., 2001). Rai et al. showed that HYAL-
2 acts as a receptor for jaagsiekte sheep retrovirus. Functionally,
membrane HYAL-2 degrades HA bound by co-receptor CD44 to
generate end products of approximately 20 kDa fragments. That
is, CD44 assists HYAL-2 in degrading HA. The HA fragments
can be endocytosed, and then HYAL-1 further degrades the HA
fragments (Puissant et al., 2014).
HYAL-1, but not HYAL-3, plays an important role
in controlling ovarian folliculogenesis by acting on the
follistatin/activin/Smad3 pathway (Dumaresq-Doiron et al.,
2012). No HYAL2 deficiency has been found in human.
Hyal2-deficient mice exhibit accumulation of extremely
large HA molecules in tissues and in circulation, and
this contributes to the development of chronic thrombotic
microangiopathy (Onclinx et al., 2015) and mild craniofacial
and vertebral abnormalities (Bourguignon and Flamion, 2016).
Megakaryocyte-derived HYAL-2 causes HA degradation, which
is needed for thrombopoiesis (Petrey et al., 2016). HYAL-3
lacks an intrinsic hyaluronidase activity in somatic cells in
vivo, whereas it participates in the hyaluronan metabolism by
augmenting the activity of HYAL-1 (Hemming et al., 2008).
HYAL-3 is abundant in the testis, and the enzymatic activity
has been detected in spermatozoa (Reese et al., 2010). PH-20,
also known as SPAM1, is a GPI-anchored hyaluronidase, which
is expressed in the lysosome-derived acrosome on a sperm’s
surface. Recombinant human PH-20 has been used clinically to
enhance drug penetration to cancer target (Frost, 2007). PH-20
facilitates fertilization by enhancing penetration of the sperm
to the ovum via cleavage of the extracellular matrix (Girish and
Kemparaju, 2007). PH-20 is expressed in sperms and breast
cells (Beech et al., 2002), and is regarded as a tumor marker for
laryngeal cancers (Godin et al., 2000).
HA DEGRADATION WITHOUT CATALYTIC
ENZYMES
HA can be degraded under enzyme-free conditions, including
acid hydrolysis (Hair et al., 2010), heat treatment by autoclave
(Pichi et al., 2012), sonication (Kubo et al., 1993), and free-
radical-based cleavage (Hrabárová et al., 2012). By sonication
using a fixed intensity at various durations, HA is broken
down to a constant size at 11 kDa after sonication. The
main sugar residues at the reducing and non-reducing termini
of depolymerized HA are N-acetylglucosamine (86%) and
glucuronic acid (98%), respectively (Kubo et al., 1993). In
contrast, we have shown that sonicated, degraded HA exhibits as
a broad range of molecular sizes from 10 to 200 kDa (Chang and
Su, 2016). The likely difference from the above report is due to
using a different type of sonication machine and the energy of
sonication used.
ROLE OF HA AND HYALURONIDASES IN
CANCER PROGRESSION AND
METASTASIS
Overproduction of HA and hyaluronidases is frequently seen in
cancer cells. This correlates with increased cancer malignancy
and metastatic potential (Sironen et al., 2011; Shepard, 2015;
Sato et al., 2016). Depletion of HA is a doable approach to
suppress cancer growth (Simpson et al., 2002). The amount of
HA surrounding invasive tumors is higher than that in non-
invasive tumors (Bertrand et al., 1992), suggesting that HA is one
of the reliable markers for tumor progression and malignancy
(Gritsenko et al., 2012). It has been shown that excessive levels
of HAS enzymes induce accumulation of HA in breast cancer,
and that these enzymes are associated with tumor aggressiveness
and poor patient outcome (Auvinen et al., 2014). Conceivably,
peritumor HA is subjected to digestion by membrane HYAL-2
with the assistance of CD44. The resulting small HA molecules
undergo conformational changes by de-coupling and re-coupling
of long and short chains due to local thermal changes by cancer-
associated inflammation. The resulting molecular hybrids are the
likely stimulators for tumor growth, and they may act as auto-
chemotactic factors for increasing cancer cell mobility (Saito
et al., 2011).
TUMOR SUPPRESSOR WWOX IS
ANCHORED ON THE CELL MEMBRANE
BY HYAL-2
Hyaluronidases PH-20, HYAL-1, and HYAL-2 induce the
expression of tumor suppressor WWOX in fibroblasts (Chang
et al., 2001, 2007; Chang, 2002). WW domain-containing
oxidoreductase, known as WWOX, FOR, and WOX1, was first
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isolated in 2000 independently by 3 groups (Bednarek et al., 2000;
Ried et al., 2000; Chang et al., 2001). HumanWWOX gene has 1.1
million bases and is located on a chromosomal common fragile
site 16q23 or FRA16D. High frequency of loss of heterozygosity
(LOH) ofWWOX gene at approximately 30–50% levels has been
shown in many types of cancer cells (Aqeilan and Croce, 2007;
Chang et al., 2007; Del Mare et al., 2009; Gardenswartz and
Aqeilan, 2014; Abu-Remaileh et al., 2015; Chang, 2015; Chang
et al., 2015; Richards et al., 2015; Schrock and Huebner, 2015).
Mutation of WWOX gene in breast cancer occurs frequently
at exons 4–9 (Ekizoglu et al., 2012). Loss of WWOX gene
expression can be due to hypermethylation of gene promoter
(Iliopoulos et al., 2005; Chang et al., 2010; Gardenswartz and
Aqeilan, 2014). When cytosolic WWOX protein relocates to the
nucleus under stress conditions, WWOX is able to maintain
genomic stability by controlling ATM activation and DNA
damage response (Abu-Odeh et al., 2014; Abu-Remaileh et al.,
2015). Most recently, WWOX-mediated suppression of cancer
cell growth has been established in Drosophila (O’Keefe et al.,
2015). Notably, null mutations ofWWOX/Wwox gene in humans
and animals lead to severe neural diseases (e.g., microcephaly,
seizure, ataxia, etc.), growth retardation, metabolic disorders,
developmental delay, and early death (Aldaz et al., 2014; Chang
et al., 2014; Alkhateeb et al., 2016; Elsaadany et al., 2016).
Nevertheless, no spontaneous cancer formation has been seen
in the newborns, arguing whether WWOX is a real tumor
suppressor.
WWOX possesses two N-terminal WW domains (containing
conserved tryptophan residues), a nuclear localization sequence,
and a C-terminal short-chain alcohol dehydrogenase/reductase
(ADH/SDR) domain (Bednarek et al., 2000; Ried et al.,
2000; Chang et al., 2001). Activation of WWOX via Tyr33
phosphorylation is essential for its proapoptotic function and
anticancer property. Under apoptotic stress, WWOX undergoes
Tyr33 phosphorylation, binds pS46-p53, and translocates with
pS46-p53 to the nucleus to induce apoptosis (Chang et al., 2001,
2003, 2005; Lin et al., 2011; Tsai et al., 2013). Both p53 and
WWOX work synergistically in inducing apoptosis. Without
WWOX, p53 is destabilized and susceptible to ubiquitination and
proteosomal degradation in the cytoplasm (Chang et al., 2005).
When both WWOX and p53 are dysfunctional, osteosarcoma
occurs in a double knockout mouse model, suggesting that both
proteins participate in normal bone development (DelMare et al.,
2016). In another functional aspect, calcium ionophore/phorbol
ester induces terminal maturation of MOLT-4 T cell acute
lymphoblastic leukemia, which is due to Ser14 phosphorylation
of WWOX, IκBα–ERK–WWOX signaling, and expression of
CD3 and CD8 (Lin et al., 2011; Huang et al., 2016).
When WWOX undergoes Lys63-linked ubiquitination at
Lys274 by E3 ubiquitin ligase ITCH, it relocates to the nucleus
and enhances cell death (Abu-Odeh et al., 2014; Abu-Remaileh
et al., 2015). In addition, vesicle trafficking protein TRAPPC6A
binds WWOX and acts as a carrier for WWOX to undergo
nuclear accumulation (Chang and Chang, 2015). Interestingly,
WWOX can be subjected to E3 ligase polycomb2 (Pc2)-mediated
SUMOylation, and this enables its suppression of DU145 prostate
cancer tumorigenesis (Choi et al., 2015). Activated tyrosine
kinase Cdc42-associated kinase (ACK1) promotes prostate
cancer progression, via binding and phosphorylating WWOX
at Tyr287 for polyubiquitination and proteosomal degradation
(Mahajan et al., 2005).
Transiently overexpressed WWOX has been shown to block
translocation of many transcription factors to the nucleus. And,
this leads to a general belief that WWOX sequesters prosurvival
transcription factors in the cytoplasm to block cancer growth
(Chang et al., 2001, 2003, 2005, 2007; Aqeilan et al., 2004;
Aqeilan and Croce, 2007; Aldaz et al., 2014; Abu-Remaileh et al.,
2015). Inducible WWOX sequesters SMAD3 in the cytoplasm
and inhibits its transcriptional function (Ferguson et al., 2013).
Nonetheless, this does not work effectively in vivo. For example,
endogenous WWOX rapidly binds and co-translocates with
CREB to the nuclei of injured neurons during sciatic nerve
transection in rats (Li et al., 2009). EndogenousWWOX does not
block the nuclear translocation of CREB, NF-κB, c-Jun, andmany
other transcription factors (Li et al., 2009; Chang et al., 2014).
HYAL-2 IS A COGNATE RECEPTOR FOR
TGF-β: SIGNALING VIA
HYAL-2-WWOX-SMAD4 TO REGULATE
CELL GROWTH OR DEATH
Epithelial cancer cells undergo epithelial-mesenchymal transition
(EMT) to turn into malignancy. TGF-β-mediated EMT requires
participation of HAS2 (Porsch et al., 2013). Overproduction of
HA is needed to drive EMT via Twist and TGF-β–Snail signaling
(Chanmee et al., 2014, 2016). TGF-β1 is growth-inhibitory to
normal epithelial cells, whereas hyaluronidase PH-20 counteracts
the effect of TGF-β1 (Chang, 1997), Chang (1998, 2002). TGF-
β1 protects murine L929 fibroblasts from the cytotoxic effect
of tumor necrosis factor (TNF), whereas transiently expressed
HYAL-1 and HYAL-2 block the TGF-β1 function (Chang,
1998). The functional antagonism is associated, in part, with
hyaluronidase-mediated rapid activation of ERK in L929 cells
and TGF-β1 blocks the activation (Chang, 2001). In the canonical
pathway, TGF-β1 binds membrane type II TGF-β receptor
(TβRII) as a cognate receptor and then recruits TβRI, followed
by phosphorylating SMAD2 and 3 and recruiting SMAD4 to
translocate to the nuclei for controlling gene transcription (Hsu
et al., 2009; Hata and Chen, 2016; Heldin and Moustakas, 2016).
Another explanation for the functional antagonism between
TGF-β1 and hyaluronidases is that membrane HYAL-2 serves
as a cognate receptor for TGF-β1 (Hsu et al., 2009). In
a non-canonical pathway, binding of TGF-β to HYAL-2
results in recruitment of tumor suppressors WWOX and
SMAD4 and their relocation into the nucleus (Hsu et al.,
2009; Chang et al., 2010). By immunoelectron microscopy,
we have shown that TGF-β1 binds membrane HYAL-2,
followed by internalization of the resulting TGF-β1/HYAL-2
complexes by endosomes and fusion with lysosomes (Hsu et al.,
2009). Whether the complex is degraded in the lysosome is
unknown. The TGF-β1/HYAL-2 complexes must have triggered
a membrane/intracellular machinery to allow the complex
internalization. The WWOX/HYAL-2 complexes can be found
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on the cell surface by immunoelectron microscopy (Hsu
et al., 2009). TGF-β1 also induces the internalization of the
WWOX/HYAL-2 complexes. When WWOX and HYAL-2 are
transiently overexpressed, TGF-β1 dramatically enhances the
activation of SMAD responsive element (8–9-fold increases),
which subsequently leads to cell death (>95% of promoter-
activated cells). This raises the possibility that HYAL-2 and
WWOX are cofactors for SMAD4 to bind the SMAD responsive
promoter DNA and control gene expression.
Binding of WWOX with HYAL-2 and SMAD4 has been
determined by co-immunoprecipitation, yeast two-hybrid
analysis, immunoelectron microscopy, and real time FRET
microscopy (Hsu et al., 2009, 2016). WWOX acts as a bridge to
interact with both proteins. The first WW domain with Tyr33
phosphorylation is able to bind both HYAL-2 and SMAD4.
However, the region(s) in HYAL-2 and SMAD4 for WWOX
binding is unknown. SMAD4 also binds to the C-terminal SDR
domain of WWOX. There is a competitive binding interaction
between SMAD4 and HYAL-2 to the WW domain of WWOX
(Hsu et al., 2016). Presumably, the HYAL-2–WWOX–SMAD4
complex is most stabilized for the binding of SMAD4 to the N-
terminal WW domain of WWOX and HYAL-2 to the C-terminal
SDR domain.
During traumatic brain injury, dramatic accumulation of the
HYAL-2–WWOX complex is found in the apoptotic nuclei of
damaged neurons in the brains of rats, suggesting a novel role of
the overly loaded HYAL-2–WWOX complex in causing neuronal
death in vivo (Hsu et al., 2016). Presumably, pericellular high
molecular weight HA enhances the binding of TGF-β1 with
HYAL-2 without transmitting the signal. Upon HA degradation
by HYAL-2, TGF-β signaling starts. It has been reported that
HA blocks TGF-β signaling by inducing trafficking of TGF-β
receptors to lipid raft-associated pools, which facilitates increased
receptor turnover (Ito et al., 2004a,b).
Taken together, there are key links that allow HYAL-2 to
disrupt the TGF-β1 signaling. First, HA affects the binding of
TGF-β1 with HYAL-2. Second, functional deficiency or defect
of the HYAL-2-WWOX-SMAD4 signaling complex may occur
in cancer cells. For example, tumor suppressor WWOX is
frequently missing in cancer cells (Bednarek et al., 2000; Chang
et al., 2001, 2003, 2007; Iliopoulos et al., 2005; Aqeilan and
Croce, 2007; Chiang et al., 2013; Gardenswartz andAqeilan, 2014;
Abu-Remaileh et al., 2015; Schrock and Huebner, 2015; Huang
et al., 2016). Lastly, the CD44-HYAL-2 complex provides spatial
hindrance for the binding of TGF-β1 with Hyal-2. CD44 is not
involved in the HYAL-2-WWOX-SMAD4 signaling (Hsu et al.,
2009).
HIGH MOLECULAR WEIGHT HA INDUCES
BUBBLING CELL DEATH VIA SIGNALING
WITH OVEREXPRESSED
HYAL-2–WWOX–SMAD4 COMPLEX
Cytosolic WWOX is anchored, in part, at the cell membrane by
HYAL-2 or Ezrin onto the cell membrane (Jin et al., 2006; Hsu
et al., 2009). HYAL-2 is inserted on the cell membrane via a GPI
linkage and is exposed onto the cell surface. WWOX is exposed
onto the cell surface via binding with HYAL-2, as determined
by immunoelectron microscopy (Hsu et al., 2009). It appears
that WWOX by itself may localize on the cell surface (Hsu
et al., 2009). However, how this works remain to be established.
Whether membrane localization of WWOX is via interaction
with other cytoskeletal proteins [e.g., merlin/NF2 and/or AMOT
(Angiomotin) Abu-Remaileh et al., 2015], is unknown and
remains to be established.
The fairly high molecular mass of HA in naked mole rats
allows them to resist cancer growth (Tian et al., 2013). How HA
blocks cancer growth is largely unknown. One report showed
that HA-binding motifs of USP17 deubiquitinating enzyme and
SDS3 (suppressor of defective silencing 3) are responsible for
HA-mediated growth suppression (Ramakrishna et al., 2012). In
addition, overexpression of endogenous HA leads to enhanced
homotypic E-cadherin mediated cell-cell adhesion, induction
of cell cycle inhibitors and suppression of G0/1 to S-phase
transition of the cell cycle, and blocking of cell proliferation,
(Bharadwaj et al., 2011). HA oligomers of approximately 2.5 ×
103 Daltons inhibit tumor growth in vivo (Ghatak et al., 2002).
Also, these oligomers suppress anchorage-independent growth
and apoptosis of cancer cells by blocking PI 3-kinase/Akt (protein
kinase B) cell survival pathway and inducing caspase activation
and apoptosis (Ghatak et al., 2002).
We validated the HA-induced endogenous HYAL-2–
WWOX–SMAD4 signaling by co-immunoprecipitation and
time-lapse tri-molecular Förster resonance energy transfer
(FRET) microscopy (Hsu et al., 2016). High molecular weight
HA (2–3 million Daltons) induces a rapid increase in the
formation of endogenous HYAL-2–WWOX–SMAD4 complex
in cells (Figure 1A). Twenty to Fourty minutes later, the complex
relocates to the nuclei in WWOX-expressing normal and cancer
cells. In WWOX-deficient cells, SMAD4 spontaneously relocates
to the nucleus without HA stimulation (Hsu et al., 2016).
Stimulation of cells with HYAL-2 antibody, or HYAL-2 antisense
expression cDNA, results in spontaneous accumulation of
WWOX and SMADs in the nucleus (Hsu et al., 2016). Together,
these observations suggest that endogenous HYAL-2 and
WWOX regulate each other in a reciprocal manner and act
together in blocking nuclear translocation of SMAD proteins.
HA-mediated signaling of endogenous HYAL-2–WWOX–
SMAD4 drives the formation of ectopic complexes of ecfp-
SMAD4–egfp-HYAL-2–DsRed-WWOX and ecfp-SMAD4–egfp-
WWOX–DsRed-p53 (Hsu et al., 2016). HA increases the
complex formation of ectopic ecfp-SMAD4–egfp-HYAL-2–
DsRed-WWOX with time, and the complex relocates to
the nucleus. Interestingly, cells undergo bubbling cell death
(Figure 1B). Bubbling cell death is not identical to apoptosis,
and has been defined as “formation of a single nitric oxide-
containing bubble from the nucleus per cell and release of
this swelling bubble from the cell surface to extracellular space
that causes cell death.” (Chen et al., 2015; Chang, 2016).
Bubbling cell death is caspase-independent, and exhibits no
DNA fragmentation and flip-over of phosphatidylserine. Also,
HA increases the complex formation of ectopic ecfp-SMAD4–
egfp-WWOX–DsRed-p53with time, and the cytosolic complex
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FIGURE 1 | HA activates endogenous HYAL-2–WWOX–SMAD4 signal
pathway. (A) A schematic graph for high molecular weight HA-induced
signaling of HYAL-2–WWOX–SMAD4 complex is shown. Formation of the
endogenous complex is increased with time. Relocation of the complex to the
nucleus occurs in 20–40 min post stimulation. (B) As determined by
time-lapse tri-molecular FRET microscopy (Hsu et al., 2016; Huang et al.,
2016), HA activates the endogenous HYAL-2–WWOX–SMAD4 signaling and
increases the complex formation of ectopic
ECFP-SMAD4–EGFP-HYAL-2–DsRed-WWOX to undergo nuclear
accumulation. Cells undergo bubbling cell death (Chen et al., 2015; Chang,
2016). (C) Also, HA induces the complex formation of ectopic
ECFP-SMAD4—EGFP-WWOX—DsRed-p53, and membrane blebbing occurs
in cells without leading to death. The complex fails to relocate to the nucleus.
localizes in the cytoplasm and causes membrane blebbing
(Figure 1C). No cell death occurs. Failure of cell death is probably
due to localization of the SMAD4–WWOX–p53 signaling
complex in the cytoplasm. Malignant cancer cells are generally
devoid of tumor suppressors WWOX, SMAD4, and p53. Or, they
possess protein mutants. Conceivably, HA-induced signaling of
HYAL-2–WWOX–SMAD4 is defective. This allows cancer cells
gain growth advantage and degraded HA-increased metastasis.
Calcium ionophore/phorbol ester induces the signaling of IκBα–
ERK–WWOX for maturation of T cell leukemia, whereas HA has
no effect in inducing the signaling event (Hsu et al., 2016; Huang
et al., 2016).
ZFRA BINDS MEMBRANE HYAL-2 AS A
RECEPTOR IN SPLEEN HYAL-2+ CD3−
CD19− Z LYMPHOCYTE
The HYAL-2–WWOX–SMAD4 signaling is involved in
anticancer response in vivo. Zfra peptide binds membrane
HYAL-2 as a receptor to activate a novel non-T/non-B spleen
HYAL-2+ CD3− CD19− Z lymphocyte for memory anticancer
response (Lee et al., 2015). Zfra, zinc finger-like protein that
regulates apoptosis, is a naturally occurring 31-amino-acid
protein (Hsu et al., 2005, 2008; Hong et al., 2007a; Degterev
and Yuan, 2008; Dudekula et al., 2010; Lee et al., 2015). Like
many peptide drugs, Zfra has a good potential in anticancer
therapeutics (Li and Cho, 2010; Fosgerau and Hoffmann,
2015). Transiently overexpressed Zfra nullifies the functions of
nuclear factor NF-κB, cJun N-terminal kinase 1 (JNK1), and
tumor suppressors p53 and WWOX (Hsu et al., 2005; Hong
et al., 2007a). Zfra participates in the pathway of mitochondrial
apoptosis (Hsu et al., 2008). Synthetic Zfra peptide (e.g., Zfra1-31
or Zfra4-10) undergoes self-polymerization in vivo and in vitro
(Lee et al., 2015). Polymerized Zfra peptide stays on the cell
surface only. It cannot be internalized by cells and fails to induce
cell death in vitro (Lee et al., 2015).
Zfra effectively prevents and blocks the growth of at least 10
types of cancer cells in vivo (Lee et al., 2015; Chang et al., 2016a,b).
For example, T cell-deficient nude mice received an aliquot of
full-length Zfra1-31 or Zfra4-10 at 2 mM in sterile PBS (or PBS
only) via tail vein injections once per week for 3 consecutive
weeks. After resting for 1 week, mice were then inoculated with
skin basal cell carcinoma (BCC) cells (or other types of cancer
cells) onto two subcutaneous sites in both flanks. Compared
to controls, Zfra significantly blocked BCC growth by 50–75%
(Lee et al., 2015). Alteration of a conserved phosphorylation
site Ser8 to Gly8 abolishes the peptide polymerization and
its anticancer effect in vivo, suggesting that Ser8 participates
in peptide polymerization (Lee et al., 2015). Heterozygous
Wwox+/− mice with exon 2–4 ablation spontaneously develop
tumor approximately at age one (Aqeilan et al., 2007), and Zfra4-
10 completely cures the tumor in 50 days (Lee et al., 2015). Zfra is
very powerful in blocking cancer metastasis and cancer stem cell
development (Lee et al., 2015).
POLYMERIZED ZFRA ACTIVATES Z CELL
FOR MEMORY ANTICANCER RESPONSE
IN VIVO
Zfra effectively suppresses tumor-induced spleen splenomegaly
by near 100% reduction (Lee et al., 2015). When mice receive
Zfra peptides, either full length or Zfra4-10, via tail veins, the
peptide is mainly trapped in the spleens but not in other organs
(Lee et al., 2015). Zfra is not toxic to organs, including spleen,
liver, lung, brain, skin, and other organs (Lee et al., 2015). Zfra-
treated normal mice survive for the entire life span. Zfra activates
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memory spleen cells for cancer targeting via interacting with
membrane HYAL-2 (Lee et al., 2015). When spleen cells are
isolated from Zfra-treated nude mice, followed by transferring
to naïve nude mice via tail vein injections, these cells confer
resistance to cancer growth in the recipient mice (Figure 2; Lee
et al., 2015). Naïve Z spleen cells are around 25–29% in the spleen
of normal BALB/c mice, and spleen T and B cells 16 and 26%,
respectively. In stark contrast, when tumor cells are growing in
immune competent or deficient mice, these mice have 0.0–3.3%
Z cells in the spleen (Lee et al., 2015). Binding of Zfra with HYAL-
2 has been determined by co-immunoprecipitation and confocal
microscopy (Lee et al., 2015). Importantly, Z cell can be activated
in vitro by Zfra and works in vivo to prevent and block cancer
growth (Lee et al., 2015).
HOW DOES Z CELL WORK IN VIVO?
“Immunization” of immune-competent and -deficient mice with
Zfra peptides drives Z cell activation. No adjuvant is needed.
Activated Z cells recognize many types of cancer cells, suggesting
that there is a common antigen in the polymerized Zfra, which
shares structural similarity with antigens on the surface of cancer
cells. Notably, the Z cell level in the spleen drops dramatically
down to 0–2% in tumor-growing mice. Whether Z cell has
relocated to the cancer lesions is not known. Naïve Z cell is not
“educated” or activated even in the presence of cancer antigens
in the circulation. Accordingly, when spleen cells are isolated
from naïve mice and then educated them with Zfra in vitro, the
activated Z cell suppresses the ongoing growth of cancer in mice
(Lee et al., 2015). Despite the so-called immunodeficient status,
nude and NOD-SCID mice can be treated with Zfra to activate
their Z cell populations to fight against cancer.
Both high molecular weight HA and TGF-β1 trigger the
HYAL-2–WWOX–SMAD4 signaling (Hsu et al., 2009, 2016).
Zfra induces capping of Hyal-2 on the cell surface (Hsu
et al., 2009), and this may lead to WWOX phosphorylation at
Tyr33 (p-WWOX) for interacting with HYAL-2, followed by
internalization of HYAL-2–WWOX, along with Smad4. Perhaps,
Zfra-mediated capping of Hyal-2 on the cell surface appears
to be necessary to establish the induced memory anticancer
response. Indeed, anti-Hyal-2 antibody and sonicated HA are
able to achieve similar anticancer effects (Chang and Su, 2016).
Sonicated HA has an altered that allows its strong binding with
membrane HYAL-2 for provoking memory anticancer response.
CONCLUSION AND PERSPECTIVES
Here, we detail the functional properties of HA, hyaluronidases
and WWOX in normal physiology, pathological conditions, and
cancer progression. We have also described TGF-β1 and HA-
activated HYAL-2–WWOX–SMAD4 signaling, and the signaling
related activation of SMAD responsive element and cell death.
Whether the signaling is responsible for Zfra-mediated Z cell
activation in conferring anticancer response in vivo is discussed.
A likely scenario for Zfra-mediated Z cell activation is that Zfra
binds membrane HYAL-2, which leads to recruit WWOX and
then SMAD4. The resulting complex HYAL-2–WWOX–SMAD4
translocates to the nucleus for gene transcription. Alternatively,
Zfra binds directly to membrane-localized WWOX (Hsu et al.,
2009). Supporting evidence from yeast two-hybrid and FRET
analyses revealed that non-activated WWOX is a “closed” form
due to the binding of N-terminal WW domains with C-terminal
SDR domain. Upon activation, Tyr33 becomes phosphorylated
that leads to formation of an “open” form with WW and
FIGURE 2 | An in vivo model for Zfra-mediated Z cell activation for cancer prevention and treatment. Immune competent or deficient mice receive tail vein
injections with full-length Zfra1-31 or Zfra4-10 peptide. Injected Zfra directly goes to the spleen but not other organs (Lee et al., 2015). Zfra activates spleen HYAL-2+
CD3− CD19− Z cell. Z cell probably goes to the cancer lesions to block tumor growth. Transfer of the activated Z cell to naïve mice or tumor-growing mice results in
suppression of tumor growth. Without Z cell activation, tumor cells continue to grow.
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SDR domains in a dissociated state. Presumably, binding of
Zfra to WWOX leads to Tyr33 phosphorylation and Ser14
de-phosphorylation, and the open form has an exposure of
WWOX7-21 motif for Z cell activation. We have established that
Tyr33-phosphorylated WWOX is an activated form for cancer
suppression (Chang et al., 2001, 2003, 2007; Chiang et al., 2013;
Abu-Remaileh et al., 2015; Huang et al., 2016). Nevertheless, how
the extracellular polymerized Zfra peptide regulates the specific
site phosphorylation in WWOX remains to be established.
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